Abstract 1371
Background
Persistence with dmab therapy may impact clinical efficacy in preventing skeletal-related events (SREs), but is undetermined in real-world.
Methods
Single-arm, prospective, observational, non-interventional study in pts with BM from ST (breast, prostate, lung, other) treated with dmab in real-world in Austria, Czech Republic, Hungary, Slovakia, and Bulgaria between 10/2012 and 05/2017. Primary objective: persistence at 24 weeks (wks) (=6 dmab subcutaneous injections; permissible intervals: 4±1 wks). Secondary objectives: persistence at 48 wks, time to non-persistence, calcium (Ca) / vitamin D supplementation, (serious) adverse drug reactions ([S]ADRs) incl. non-adjudicated osteonecrosis of the jaw (ONJ) rate.
Results
598 patients were included, 451 completed 24 wks, 387 completed 48 wks of study, 211 discontinued before 48 wks due to death (n = 80), loss to follow-up (n = 35), informed consent withdrawal (n = 7), dmab discontinuation (n = 56, [S]ADRs [n = 5]), other reasons (n = 28). 10.9% (n = 65) had previous SREs. Persistence with dmab and safety are shown in the table. Persistence at 24/48 wks was 62.6/40.1% overall, 69.5/45.5% for breast, 69.3/46.6% for prostate, 26.1/10.9% for lung, and 40.7/21.1% for other cancers. Median (IQR) duration of dmab exposure was 309 days (168.0, 319.0) and 11 doses (6.0, 12.0). The most frequent reason for non-persistence was the violation of one time window. Overall, analgesics use trended towards weaker analgesics over time, with ∼60% of pts not requiring any analgesics. Serum Ca remained within the normal range of 2.2 to 2.7 mmol/L throughout the study. ∼70% of pts received Ca and vitamin D supplements at baseline, increasing to ∼80% at dose 2 and steadily decreasing thereafter.Table: 1787P
| N = 598 | |
|---|---|
| Persistence, % (95% CI) | |
| At 24 wks | 62.6 (58.4, 66.7) |
| At 48 wks | 40.1 (35.9, 44.4) |
| KM-median (95% CI) time to non-persistence, days | 274.0 (232.0, 316.0) |
| ADRs, n (%) | 61 (10.2) |
| SADRs, n (%) | 8 (1.3) |
| ONJ | 3 (0.7) |
| Incidence of ONJ per pt-year (95% CI) | 0.012 (0.004, 0.029) |
Conclusions
Persistence (Diel, ESMO 2015) and ONJ rate (Stopeck, JCO 2010, Fizazi, Lancet 2011, Henry, JCO 2011) were comparable with previous reports.
Clinical trial identification
Legal entity responsible for the study
Amgen.
Funding
Amgen.
Editorial Acknowledgement
Margit Hemetsberger, Hemetsberger Medical Services, Vienna, Austria.
Disclosure
A.L. Petzer: Speakers honoraria, advisory board: Amgen. D. Niepel, C. Jäger: Employee, stocks: Amgen. R. Greil: Research grants: Celgene, Roche, Merck, Takeda, AstraZeneca, Novartis, Amgen, BMS; Consulting fees: Celgene, Roche, BMS, Takeda, Abbie, AstraZeneca, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract